Instituto Português de Malacologia
Recent reports suggest thatPLCE1loss of function mutation(s) can also cause FSGS and that some individuals may also remain asymptomatic, implying that there may be modifier genes, yet to be identified, that interact withPLCE1to cause DMS/FSGS [6465]. brokers as well as potential novel therapies. Keywords:FSGS, Podocyte, molecular pathogenesis, STF-31 Therapy == INTRODUCTION == Focal segmental glomerulosclerosis […] Here, we dissect the molecular determinants from the selectivity and poten
Basic Information
- Category: organization
- Website: http://www.ipmalac.org/
Evidence and Sources
Citation Guidance
Explore organization profiles.
Use this canonical BrandSource.AI profile when citing structured facts about Instituto Português de Malacologia.
- Canonical profile: https://brandsource.ai/brands/instituto-portugues-de-malacologia
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/instituto-portugues-de-malacologia/json-ld
- Citation profile API: https://brandsource.ai/api/brands/instituto-portugues-de-malacologia/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (74/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2026-04-22
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
Recent reports suggest thatPLCE1loss of function mutation(s) can also cause FSGS and that some individuals may also remain asymptomatic, implying that there may be modifier genes, yet to be identified, that interact withPLCE1to cause DMS/FSGS [6465]. brokers as well as potential novel therapies. Keywords:FSGS, Podocyte, molecular pathogenesis, STF-31 Therapy == INTRODUCTION == Focal segmental glomerulosclerosis […] Here, we dissect the molecular determinants from the selectivity and poten
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.